Highlights
Cognitive and Functional Improvement
Gamma tACS significantly improved global cognitive functions, activities of daily living, and associative memory compared to sham stimulation, with notable differences in CDR-SB and ADAS-cog scores.
Safety and Feasibility
The study confirms that home-based administration of 40 Hz tACS is feasible, safe, and well-tolerated by patients with prodromal and mild Alzheimer disease (AD), achieving high adherence rates.
Neurophysiological Engagement
Treatment led to increased gamma band power and enhanced cholinergic neurotransmission, providing a biological basis for the observed clinical benefits.
Optimal Treatment Duration
Data suggest that an 8-week treatment course represents an ideal duration, as no additional benefits were observed after extending the treatment to 16 weeks.
Introduction: Addressing the Gamma Deficit in Alzheimer Disease
Alzheimer disease (AD) remains one of the most significant challenges in modern neurology, characterized by progressive cognitive decline and the accumulation of amyloid-beta and tau proteins. Beyond these pathological hallmarks, AD is increasingly recognized as a disorder of neural circuitry and oscillatory dysfunction. Specifically, dysregulation of gamma-frequency (approximately 40 Hz) oscillations has been linked to impaired cognitive processing and memory consolidation.
Transcranial alternating current stimulation (tACS) has emerged as a promising non-invasive neuromodulation technique capable of entraining these cerebral oscillations at specific frequencies. By targeting the precuneus—a central hub of the Default Mode Network (DMN) that is often affected early in the AD continuum—researchers aimed to restore rhythmic neural activity and improve clinical outcomes. This study investigates whether a home-based, patient-delivered tACS protocol can provide a scalable and effective therapeutic intervention.
Study Design and Methodology
This double-blind, randomized, sham-controlled clinical trial with an open-label extension phase was conducted at a tertiary AD research clinic in Italy. The study enrolled 50 patients diagnosed with prodromal or mild AD, with a mean age of 67.3 years.
Intervention Protocols
Participants were randomized 1:1 to receive either active gamma tACS or sham stimulation. The active intervention involved home-based sessions (5 days per week, 60 minutes per session) for an initial 8-week double-blind phase. The stimulation was delivered at 40 Hz with a peak-to-peak intensity of 2 mA, targeting the precuneus. Following the double-blind phase, all participants entered an 8-week open-label phase where they received active gamma tACS, followed by an 8-week follow-up period.
Primary and Secondary Endpoints
The primary endpoints focused on safety, feasibility, and clinical efficacy. Clinical efficacy was measured using the Clinical Dementia Rating sum of boxes (CDR-SB), the Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog), and the Alzheimer Disease Cooperative Study-Activities of Daily Living (ADCS-ADL). Secondary endpoints included neurophysiological markers (gamma band power via EEG), cholinergic neurotransmission (via transcranial magnetic stimulation), and AD plasma biomarkers (amyloid-beta and tau levels).
Key Findings: Clinical Efficacy and Biological Impact
The trial yielded significant evidence supporting the use of gamma tACS in clinical practice. The results were categorized into clinical outcomes, neurophysiological changes, and biomarker analysis.
Clinical Outcomes
During the 8-week double-blind phase, patients receiving active gamma tACS showed superior outcomes compared to the sham group across several validated scales:
- Clinical Dementia Rating sum of boxes (CDR-SB): A significant mean difference of 0.35 (95% CI, 0.10-0.61; P = .007) favored the treatment group.
- ADAS-cog: The treatment group showed an improvement of 0.93 points over sham (95% CI, 0.50-1.36; P = .001).
- Activities of Daily Living (ADCS-ADL): A significant improvement was noted with a mean difference of -0.55 (95% CI, -0.89 to -0.21; P = .02).
- Face-Name Association Test: Associative memory improved significantly, with a mean difference of -1.14 (P ≤ .001).
In the subsequent open-label phase, participants who switched from sham to active stimulation also showed significant improvements in ADAS-cog and ADCS-ADL, suggesting that the benefits are reproducible across different patient cohorts.
Neurophysiological Results
One of the most compelling aspects of the study was the correlation between clinical improvement and brain engagement. EEG data revealed a significant increase in gamma band power following active tACS. Furthermore, measures of short-latency afferent inhibition (SAI) indicated an enhancement in cholinergic neurotransmission. This is particularly relevant given the well-established cholinergic deficit in AD and the reliance of many current pharmacological treatments (such as acetylcholinesterase inhibitors) on this system.
Safety and Biomarker Analysis
Home-based tACS was found to be safe and well-tolerated, with no serious adverse events reported. Adherence rates were high, demonstrating the feasibility of remote neuromodulation in this population. Interestingly, despite the clinical and neurophysiological improvements, no significant changes were observed in plasma levels of amyloid-beta (Aβ42/40 ratio) or p-tau. This suggests that the clinical benefits of tACS may be driven by circuit-level functional improvements rather than immediate protein clearance.
Expert Commentary: Mechanistic Insights and Clinical Implications
The Role of the Precuneus
The choice of the precuneus as a stimulation target is strategically sound. As a core component of the Default Mode Network, the precuneus is involved in self-referential processing and episodic memory. Its early vulnerability in AD makes it an ideal site for neuromodulatory intervention. By entraining gamma rhythms in this hub, tACS likely facilitates more efficient communication across the DMN and associated networks.
The Home-Based Advantage
Moving tACS from the clinic to the home represents a major paradigm shift. For patients with cognitive impairment, frequent travel to a tertiary center is a significant barrier to care. This trial demonstrates that with proper training and remote monitoring, families can successfully administer complex neuromodulation protocols, greatly increasing the scalability of the treatment.
Treatment Duration and the Plateau Effect
A critical finding of this study is that 16 weeks of treatment did not offer additional benefits over 8 weeks. This suggests a potential “ceiling effect” or a plateau in the brain’s plastic response to rhythmic stimulation. Future research should investigate whether intermittent “booster” sessions or different frequencies could further extend the clinical benefits.
Conclusion
The randomized clinical trial by Cantoni et al. provides robust evidence that home-based gamma tACS is a feasible, safe, and effective adjunct therapy for patients with prodromal and mild Alzheimer disease. By directly targeting oscillatory deficits and enhancing cholinergic tone, tACS offers a novel mechanism of action that complements existing pharmacological approaches. While the lack of change in plasma biomarkers indicates that the intervention may not modify the underlying proteinopathy in the short term, the significant gains in cognitive and functional scores are of high clinical relevance. These findings warrant larger, multicenter trials to further validate these results and optimize stimulation parameters for long-term care.
Funding and Trial Registration
This study was supported by various Italian research grants and institutional funding.
Trial Registration: ClinicalTrials.gov Identifier: NCT05643326.
References
1. Cantoni V, Casula EP, Tarantino B, et al. Home-Based Gamma Transcranial Alternating Current Stimulation in Patients With Alzheimer Disease: A Randomized Clinical Trial. JAMA Netw Open. 2025;8(12):e2546556. doi:10.1001/jamanetworkopen.2025.46556.
2. Adaikkan C, Tsai LH. Gamma Oscillations: The Rhythm of Cognitive Function and Dysfunction. Front Syst Neurosci. 2020;14:54.
3. Santarnecchi E, et al. Non-invasive Brain Stimulation in Alzheimer’s Disease: Systematic Review and Recommendations for Future Studies. J Alzheimers Dis. 2015;47(3):569-592.